GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sonendo Inc (OTCPK:SONX) » Definitions » ROE %

Sonendo (Sonendo) ROE % : -131.46% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Sonendo ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Sonendo's annualized net income for the quarter that ended in Dec. 2023 was $-43.51 Mil. Sonendo's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $33.10 Mil. Therefore, Sonendo's annualized ROE % for the quarter that ended in Dec. 2023 was -131.46%.

The historical rank and industry rank for Sonendo's ROE % or its related term are showing as below:

SONX' s ROE % Range Over the Past 10 Years
Min: -112.9   Med: -92.24   Max: -74.08
Current: -112.9

During the past 5 years, Sonendo's highest ROE % was -74.08%. The lowest was -112.90%. And the median was -92.24%.

SONX's ROE % is ranked worse than
88.34% of 806 companies
in the Medical Devices & Instruments industry
Industry Median: 0.125 vs SONX: -112.90

Sonendo ROE % Historical Data

The historical data trend for Sonendo's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonendo ROE % Chart

Sonendo Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
- - - -74.08 -110.39

Sonendo Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.38 -81.69 -116.36 -149.56 -131.46

Competitive Comparison of Sonendo's ROE %

For the Medical Devices subindustry, Sonendo's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonendo's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sonendo's ROE % distribution charts can be found below:

* The bar in red indicates where Sonendo's ROE % falls into.



Sonendo ROE % Calculation

Sonendo's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-60.919/( (81.955+28.419)/ 2 )
=-60.919/55.187
=-110.39 %

Sonendo's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-43.512/( (37.78+28.419)/ 2 )
=-43.512/33.0995
=-131.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Sonendo  (OTCPK:SONX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-43.512/33.0995
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-43.512 / 46.768)*(46.768 / 83.2435)*(83.2435 / 33.0995)
=Net Margin %*Asset Turnover*Equity Multiplier
=-93.04 %*0.5618*2.5149
=ROA %*Equity Multiplier
=-52.27 %*2.5149
=-131.46 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-43.512/33.0995
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-43.512 / -43.504) * (-43.504 / -39.38) * (-39.38 / 46.768) * (46.768 / 83.2435) * (83.2435 / 33.0995)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0002 * 1.1047 * -84.2 % * 0.5618 * 2.5149
=-131.46 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Sonendo ROE % Related Terms

Thank you for viewing the detailed overview of Sonendo's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonendo (Sonendo) Business Description

Traded in Other Exchanges
N/A
Address
26061 Merit Circle, Suite 102, Laguna Hills, CA, USA, 92653
Sonendo Inc is a commercial-stage medical technology company focused on saving teeth from tooth decay, the prevalent chronic disease globally. It has developed the GentleWave System, a technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The Company operates in two business segments, Product and Software. Product segment includes sales of the Company's GentleWave System console and related accessories and instruments. Software segment includes sales of the Company's traditional software licenses for practice management software to enable an integrated digital office for endodontists.
Executives
Bjarne Bergheim director, officer: President and CEO C/O SONENDO, INC., 2601 MERIT CIRCLE, SUITE 102, LAGUNA HILLS CA 92653
Roy T Chen officer: Chief Talent Officer C/O SONENDO, INC., 2601 MERIT CIRCLE, SUITE 102, LAGUNA HILLS CA 92653
Michael Patrick Watts officer: Chief Financial Officer C/O SONENDO, INC., 2601 MERIT CIRCLE, SUITE 102, LAGUNA HILLS CA 92653
Olav Bergheim director, 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Pudipeddi Vamsi Mohan Raj director 2820 ORCHARD PARKWAY, SAN JOSE CA 95134
Michael John Smith officer: Chief Commercial Officer C/O SONENDO, INC., 2601 MERIT CIRCLE, SUITE 102, LAGUNA HILLS CA 92653
Andrew J Kirkpatrick officer: Chief Operating Officer 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
General Atlantic, L.p. director, 10 percent owner 55 EAST 52ND STREET, 33RD FLOOR, NEW YORK NY 10055
Bihl Anthony P Iii director 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Mehrezad Khakpour officer: Chief Technology Officer C/O SONENDO, INC., 2601 MERIT CIRCLE, SUITE 102, LAGUNA HILLS CA 92653
Jacqueline Arnold Collins officer: VP, General Counsel C/O SONENDO, INC., 2601 MERIT CIRCLE, SUITE 102, LAGUNA HILLS CA 92653
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
General Atlantic (soi), L.p. 10 percent owner C/O GENERAL ATLANTIC SERVICE COMPANY, LP, 55 EAST 52ND STREET, 33RD FLOOR, NEW YORK NY 10055
General Atlantic Partners (bermuda) Eu, L.p. 10 percent owner C/O GENERAL ATLANTIC SERVICE COMPANY LP, 55 EAST 52ND STREET, 33RD FLOOR, NEW YORK NY 10055
Gap Coinvestments V, Llc 10 percent owner 55 EAST 52ND STREET, 33RD FLOOR, NEW YORK NY 10055